"DCTH focuses on oncology, primarily cancers in the liver. The company engages in the development and clinical study of the Delcath chemosaturation system, which allows the administration of concentrated regional chemotherapy by isolating the circulatory system of the targeted organ. It delivers high doses of chemotherapeutic agents directly to the liver while limiting systemic exposure and the related side effects by filtering the blood prior to returning it to the patient."
It failed once, it will fail again. More dox on the liver doesn't work.
Delcath system did help, but the problem is that 3 people died as a result. Numerous side effects that didn't improve a patients quality of life. The liver is the main organ you really don't want a lot of chemo in the entire liver and that is the main purpose of the Delcath system, lower the doseage.
Thermodox places the doseage at the tumor site.
Yes, Liver Tumors are the most vascular tumors and they spread to other organs, which indicates there is a lot of micro cells traveling in the blood.
Even people who have a liver transplant most frequently get liver cancer again due to this. Thermodox is by far not a cure, but it can help prolong lives and provide more quality of living.
What chemo agent were they using? How long and what size margins were they targeting with RFA-or even using that at all? Are they directly injecting the chemo agent in the liver, infusing through an IV, or just preventing vascular outflow to saturate. What is the saturation level? What sizes were the tumor(s) they were targeting. Just a few minor details. If you can answer a single one of them I'll think you're a little less of an idiot.